Keeping a lid on drug prices is proving costly for ambitions to turn the UK into a life sciences superpower ...

In addition to the UK investment controversy, AstraZeneca is also dealing with legal challenges in China. The company ...

Drugmakers are growing frustrated with the National Health Service after a clawback tax unexpectedly soared, with ...

Pharma giant AstraZeneca urged Britain to improve the environment for businesses in order to drive investment, days after it ...

Destiny Pharma has joined a growing list of UK biotechs seeking to delist from the Alternative Investments Market (AIM) and return to private ownership. The Brighton-based company, which will put ...

On the company’s row with NICE and ... The MHRA has reminded pharma companies that from 1st January all medicines sold in the UK will have to comply with new labelling requirements.

The expansion is a natural progression for Upperton who already develops and manufactures small molecule and biological, ...

Pharma stocks have underperformed the market in the fourth quarter with the Stoxx Europe 600 Health Care index--which is heavily dominated by Europe's six largest pharma companies--down 9.4% against a ...

In a large freezer in the north of England sit hundreds of thousands of blood samples, stored there by an organization called the UK Biobank. A consortium of 14 pharmaceutical companies will now ...

and simplifies Royalty Pharma’s corporate structure. Second, the Board has approved a new $3 billion share repurchase program as part of the company’s evolving approach to returning capital to ...

In the tough market conditions last year, investors and big pharma ... company (to get funding),” said Jodi Cook, president and CEO of Skylark Bio. “This year, clearly, clinical-asset ...